KR20220070249A - 단일특이적 및 다중특이적 항체 - Google Patents

단일특이적 및 다중특이적 항체 Download PDF

Info

Publication number
KR20220070249A
KR20220070249A KR1020227013335A KR20227013335A KR20220070249A KR 20220070249 A KR20220070249 A KR 20220070249A KR 1020227013335 A KR1020227013335 A KR 1020227013335A KR 20227013335 A KR20227013335 A KR 20227013335A KR 20220070249 A KR20220070249 A KR 20220070249A
Authority
KR
South Korea
Prior art keywords
seq
antibody
binding
amino acid
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227013335A
Other languages
English (en)
Korean (ko)
Inventor
얀빈 리앙
Original Assignee
베이징 스타맵 바이오메드 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 스타맵 바이오메드 테크놀로지 리미티드 filed Critical 베이징 스타맵 바이오메드 테크놀로지 리미티드
Publication of KR20220070249A publication Critical patent/KR20220070249A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227013335A 2019-09-27 2020-09-28 단일특이적 및 다중특이적 항체 Pending KR20220070249A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962907275P 2019-09-27 2019-09-27
US62/907,275 2019-09-27
US202062989327P 2020-03-13 2020-03-13
US62/989,327 2020-03-13
PCT/US2020/053064 WO2021062361A2 (en) 2019-09-27 2020-09-28 Monospecific and multi-specific antibodies

Publications (1)

Publication Number Publication Date
KR20220070249A true KR20220070249A (ko) 2022-05-30

Family

ID=75166476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013335A Pending KR20220070249A (ko) 2019-09-27 2020-09-28 단일특이적 및 다중특이적 항체

Country Status (8)

Country Link
US (1) US20230340157A1 (https=)
EP (1) EP4034549A4 (https=)
JP (1) JP2022549362A (https=)
KR (1) KR20220070249A (https=)
CN (1) CN115052884B (https=)
AU (1) AU2020353182A1 (https=)
CA (1) CA3156160A1 (https=)
WO (1) WO2021062361A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022109987A1 (en) * 2020-11-27 2022-06-02 Shanghai Benemae Pharmaceutical Corporation Novel anti-lag3 antibodies and methods of making and using the same
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
US20250388669A1 (en) * 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
WO2023224412A1 (ko) * 2022-05-19 2023-11-23 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体
CN118255894A (zh) * 2022-12-27 2024-06-28 广东菲鹏制药股份有限公司 一种双特异性结合分子及其应用
WO2025101526A1 (en) * 2023-11-06 2025-05-15 Beijing Starmab Biomed Technology Ltd Multi-specific cancer-targeting antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517789A (ja) * 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
EP2658869B1 (en) * 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
WO2014198748A1 (en) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
PL3560954T3 (pl) * 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
EP3502142B1 (en) * 2016-06-22 2021-10-27 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Bispecific antibody and antibody conjugate for tumour therapy and use thereof
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
EP3724338A4 (en) * 2017-12-14 2021-09-29 Salk Institute for Biological Studies GENETICALLY CODED FLUORESCENT IRON FERRITIN NANOPARTICLE PROBES FOR INTRACELLULAR TARGET DETECTION BY FLUORESCENT AND ELECTRONIC MICROSCOPY
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒
US20210324477A1 (en) * 2020-04-21 2021-10-21 Grail, Inc. Generating cancer detection panels according to a performance metric
US11791597B2 (en) * 2021-02-05 2023-10-17 Aptiv Technologies (2) S.À R.L. Flexible electrical bus bar and method of manufacturing the same
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体

Also Published As

Publication number Publication date
AU2020353182A1 (en) 2022-04-14
US20230340157A1 (en) 2023-10-26
CN115052884B (zh) 2026-03-17
JP2022549362A (ja) 2022-11-24
CN115052884A (zh) 2022-09-13
WO2021062361A2 (en) 2021-04-01
CA3156160A1 (en) 2021-04-01
EP4034549A2 (en) 2022-08-03
EP4034549A4 (en) 2024-03-06
WO2021062361A3 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
JP7692448B2 (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
US20230374131A1 (en) Humanized or chimeric cd3 antibodies
KR20220070249A (ko) 단일특이적 및 다중특이적 항체
AU2020252556B2 (en) Heavy chain antibodies binding to PSMA
US20230374130A1 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
JP2022122972A (ja) Ｄｌｌ３標的多重特異性抗原結合分子およびその使用
JP7469292B2 (ja) 抗ｂｔｌａ抗体
US20220064337A1 (en) Antigen binding formats for receptor complexes
JP2023532129A (ja) Ｂｃｍａに結合する多重特異性抗体
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
KR20180021875A (ko) 다중특이적 결합 단백질
HK40080982A (en) Monospecific and multispecific antibodies
CN121975011A (en) Monospecific and multispecific antibodies
WO2025101526A1 (en) Multi-specific cancer-targeting antibodies
WO2025101525A1 (en) Monospecific and multi-specific antibodies
HK40092168A (en) Humanized or chimeric cd3 antibodies
HK40092168B (en) Humanized or chimeric cd3 antibodies
JP2026506240A (ja) Ｍｕｃ１及びｃｄ１６ａ抗体ならびに使用方法
HK1231369B (en) Humanized or chimeric cd3 antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220421

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application